Evidence map›Paper›PMID 27189672›Full record

ArticleStatistics in medicine2016

Utility-based designs for randomized comparative trials with categorical outcomes.

Thomas A Murray, Peter F Thall, Ying Yuan

Abstract read
In one paragraph

Article in Statistics in medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Estimation and Optimization of Composite Outcomes.Journal of machine learning research : JMLR · 2021
    Article
  5. Article
  6. Article
  7. Optimizing natural killer cell doses for heterogeneous cancer patients on the basis of multiple event times.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019
    Article
  8. Review
  9. Article
  10. Article
  11. Clinical Trial Design as a Decision Problem.Applied stochastic models in business and industry
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Thomas A MurrayDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Unit 1411, P.O. Box 301402, Houston, TX, 77030-1402, U.S.A.. tamurray@mdanderson.org.
Peter F ThallDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Unit 1411, P.O. Box 301402, Houston, TX, 77030-1402, U.S.A.
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Unit 1411, P.O. Box 301402, Houston, TX, 77030-1402, U.S.A.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Targeting the PI3K Signaling Pathway in Endometrial CarcinomaP50CA098258 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BODURKA, DIANE · 2003 to 2020
$32.0M
STATISTICAL METHODS FOR COMPLEX CANCER TRIALSR01CA083932 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THALL, PETER F · 2000 to 2017
$2.3M
Bayesian Adaptive Designs for Oncology Clinical Trials with Late-onset OutcomesR01CA154591 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI YUAN, YING · 2011 to 2014
$1.2M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA098258NCI NIH HHS R01 CA083932NCI NIH HHS R01 CA154591
6 · The paper itself

Abstract

A general utility-based testing methodology for design and conduct of randomized comparative clinical trials with categorical outcomes is presented. Numerical utilities of all elementary events are elicited to quantify their desirabilities. These numerical values are used to map the categorical outcome probability vector of each treatment to a mean utility, which is used as a one-dimensional criterion for constructing comparative tests. Bayesian tests are presented, including fixed sample and group sequential procedures, assuming Dirichlet-multinomial models for the priors and likelihoods. Guidelines are provided for establishing priors, eliciting utilities, and specifying hypotheses. Efficient posterior computation is discussed, and algorithms are provided for jointly calibrating test cutoffs and sample size to control overall type I error and achieve specified power. Asymptotic approximations for the power curve are used to initialize the algorithms. The methodology is applied to re-design a completed trial that compared two chemotherapy regimens for chronic lymphocytic leukemia, in which an ordinal efficacy outcome was dichotomized, and toxicity was ignored to construct the trial's design. The Bayesian tests also are illustrated by several types of categorical outcomes arising in common clinical settings. Freely available computer software for implementation is provided. Copyright © 2016 John Wiley & Sons, Ltd.

Indexed as

AlgorithmsRandomized Controlled Trials as TopicBayes TheoremHumansProbabilitySample SizeSoftwareBayesian methodsDirichlet-multinomialmultiple outcomesoncologyrandomized comparative trialsutility elicitation

Identifiers

PMID27189672
PMCPMC5048520
OpenAlexW2407984452

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.